The global cancer vaccines market, valued at US$10.23 billion in 2023, is forecasted to grow at a robust CAGR of 8.6%, ...

Interleukin Inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a CAGR of 12.6%. Mr. Shah Coherent Market Insights Pvt. Ltd.

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

The Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects. The primary endpoint is safety ...

As 2024 draws to a close, we explore five stocks to buy for a new year that promises opportunity alongside uncertainty ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Survival Rate and 37% Reduction in Risk of Death Multiple Patients with Complete Responses (CRs) and/or Partial Response (PR) ...

CHRISTMAS is a very busy time of the year for the NHS but it is also a pioneering anniversary when numerous life-saving medical discoveries ...

Duality Biologics and GSK enter into an exclusive option agreement to exploit gastrointestinal cancer target, DB-1324 - On December ...